Clinical Trial Detail

NCT ID NCT03358472
Title Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Fluorouracil

Epacadostat + Pembrolizumab

Cetuximab + Cisplatin

Age Groups: adult senior

No variant requirements are available.